A Study of LY2140023 in Patients With Schizophrenia
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to
acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as
compared to placebo.